Relapsed rhabdomyosarcoma (RMS) represents a significant therapeutic challenge. Nearly
one-third of patients diagnosed with localized RMS and over two-thirds of patients with …

Rhabdomyosarcoma (RMS) is a malignant tumor of mesenchymal origin thought to arise
from cells committed to a skeletal muscle lineage. With approximately 250 cases diagnosed …

Summary Background Data The literature on adult rhabdomyosarcoma is limited. Few
studies have identified predictors of long-term survival in this patient population. Methods …

Purpose Evaluation of primary tumor-, treatment-, and patient-related factors predicting
relapse pattern, risk, and survival after relapse with the aim to design a risk-adapted, tumor …

Background The purpose of this study was to evaluate risk and response–based multi‐agent
therapy for patients with rhabdomyosarcoma (RMS) at first relapse. Methods Patients with …

Purpose To identify risk factors associated with outcome in children with metastatic
rhabdomyosarcoma in a large cohort of patients Patients and Methods Pooled data were …

Background The prognosis for patients with metastatic rhabdomyosarcoma (RMS) remains
largely unsatisfactory despite the adoption of intensive multimodal therapy. To assess the …

Purpose Patients with non‐metastatic rhabdomyosarcoma (RMS) have a cure rate of 50–
90%, but up to one‐third of them experience mostly a local recurrence. Second‐line …

BACKGROUND Childhood rhabdomyosarcoma (RMS) has a relatively good prognosis.
Outcome for adults with this disease is poorly documented due to its rarity. METHODS The …

PURPOSE The primary aim of this clinical trial was to prioritize bevacizumab or temsirolimus
for additional investigation in rhabdomyosarcoma (RMS) when administered in combination …